Anaphore Buys Chinese Firm, Gains $15M In Funding

La Jolla-based Anaphore, a startup biopharmaceuticals developer, said today that it has acquired a Chinese firm, RuiYi Inc., and closed on the second tranche of its Series A financing, worth $15M. Anaphore said it acquired RuiYi to gain access to the Shangai-based firm's biologics drug discovery platform, targeting G protein coupled receptors (GPCRs). Financial details of that buy were not disclosed. In addition, Anaphore said it has closed on $15M in new funding, which is the second tranche of its $38M Series A financing round. Investors in that funding included 5AM Ventures, Versant Ventures, Apposite Capital, SR One, Merck Serono Ventures and Aravis. More information »